Two children. Same diagnosis. Same prescription. One improves. The other has side effects so bad the family stops the medication after a week.
The pediatrician calls it trial and error. Says it takes time to find the right fit. Says this is normal.
It does not have to be.
Your liver breaks down medication. That much most parents know. What most parents do not know is that how fast it does that is largely determined by your genes.
There is a family of enzymes in the liver responsible for processing most psychiatric medications. Based on which gene variants a child carries, they fall into one of four categories.
These are not small numbers. They represent real children whose experiences on medication, the side effects, the apparent failures, were being explained by guesswork when genetics could have answered it from day one.
Metabolizer status is only part of the picture. Beyond how the body processes a drug, there are genes that affect how the brain responds to it.
There is an enzyme that breaks down dopamine specifically in the prefrontal cortex, the part of the brain responsible for focus, impulse control, and executive function. How efficiently that enzyme works determines, in part, how a child's brain responds to stimulant medication.
of children in our patient data carried the variant associated with higher baseline dopamine and greater sensitivity to stimulants. For these children, standard doses often amplify anxiety rather than improve focus. That is not a treatment failure. It is a genetic profile that a standard checklist appointment will never surface.
Then there is a receptor gene that affects how the brain responds to methylphenidate, one of the most commonly prescribed stimulant medications for ADHD.
of our patients carried a variant associated with lower odds of methylphenidate working for the inattentive presentation of ADHD. That means the majority of children we see are carrying genetics that reduce the likelihood of the most commonly prescribed first-line treatment working as expected.
That is not a reason to give up on medication. It is a reason to test before you prescribe.
There is a third layer, and it ties directly to what we have written about before.
The MTHFR gene controls a process that affects how the body produces neurotransmitters including dopamine and serotonin. Children with MTHFR variants often cannot efficiently process standard forms of B vitamins, which means their body's ability to regulate attention and mood is compromised at a foundational level, before any medication decision is even made.
of our patients carry at least one MTHFR variant, meaningfully higher than general population rates. This is why nutrition and genetics are not separate conversations at Nira. They are the same conversation viewed from different angles.
Addressing the methylation pathway through the right form of supplementation is often part of what makes the broader plan work. And it is part of why some children's scores improve significantly before medication is ever introduced.
Genomic testing is one input. It is not destiny. We combine it with biomarkers, clinical history, and response to nutritional optimization before making any recommendation. A genetic result tells us where to look, not what to conclude.
What it changes is this: instead of starting a child on a standard dose of a first-line medication and waiting six weeks to see what happens, we begin from a position of knowing. We know how that child's body is likely to process the medication. We know how their brain is wired to respond to it. We know whether their methylation pathway is working against them.
That is not a marginal improvement over trial and error. It is a different category of care.
Your child is not a standard dose. They never were.
Book a free 20-minute discovery call with Dr. Ali. It's not a pitch. It's a conversation about your child and whether Nira is the right next step for your family.
Not ready yet? Try Atlas, our free behavior and sleep tracking app, built for parents still figuring out the patterns.